Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil

INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5-Is) have an excellent efficacy and tolerability profile and remain the first-line choice for the treatment of erectile dysfunction (ED). However, ED is still an underdiagnosed and undertreated condition, and many men prematurely discontinue the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jannini, Emmanuele A., Droupy, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377427/
https://www.ncbi.nlm.nih.gov/pubmed/30522978
http://dx.doi.org/10.1016/j.esxm.2018.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377427/
https://www.ncbi.nlm.nih.gov/pubmed/30522978
http://dx.doi.org/10.1016/j.esxm.2018.10.005

Ejemplares similares